Trial Profile
Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs BI 690517 (Primary) ; Eplerenone
- Indications Diabetic nephropathies
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Aug 2020 Status changed from suspended to completed.
- 04 Jun 2020 Planned End Date changed from 30 Dec 2020 to 13 Jul 2020.
- 04 Jun 2020 Planned primary completion date changed from 15 Jul 2020 to 8 Jul 2020.